Pineal region glioblastomas display features of diffuse midline and non-midline gliomas

被引:12
|
作者
D'Amico, Randy S. [1 ]
Zanazzi, George [2 ]
Wu, Peter [1 ]
Canoll, Peter [2 ]
Bruce, Jeffrey N. [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Neurol Surg, New York, NY 10027 USA
[2] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA
关键词
Pineal tumor; Pineal gland; Pineal glioma; Glioblastoma; Brain tumor; Histone H3 K27M; 3RD VENTRICULOSTOMY; PARENCHYMAL TUMORS; ENDOSCOPIC BIOPSY; MULTIFORME; MANAGEMENT; RESECTION; CLASSIFICATION; DISSEMINATION; TEMOZOLOMIDE; EXPERIENCE;
D O I
10.1007/s11060-018-2931-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pineal region glioblastomas (GBM) are very rare, with approximately 46 cases described in the literature. The epidemiology, pathogenesis, and treatment of these lesions are poorly characterized. We identified all cases of pineal region GBM treated surgically at our institution between 1990 and 2017. Demographic and clinical follow-up data were extracted from the medical records for all cases. Pathology was reviewed and classified according to 2016 World Health Organization (WHO) criteria. Specific attention was given to the frequency of histone H3 K27M mutations in these midline gliomas. Eight patients (seven men, one woman) with pineal region GBM, WHO grade IV, were identified. The most common presenting symptoms were headache (75%), vision changes (75%), and gait imbalance/ataxia (50%). Median age at diagnosis was 48.5 years (range 36-74 years). Radical subtotal resection, via a supracerebellar infratentorial approach, was achieved in 75% of patients. Review of the surgical pathology revealed seven primary GBMs (including one giant cell GBM) and one pineal region GBM that developed three years after resection of a pineal parenchymal tumor of intermediate differentiation. No cases demonstrated evidence of IDH-1 R132H mutation (N = 6) or 1p/19q co-deletion (N = 3). One case tested positive for the histone H3 K27M-mutation. Targeted exome sequencing of 467 cancer-related genes revealed nonsense mutations in ATRX and NF1. Adjuvant radiation and chemotherapy was employed in 87.5% and 75.0% of patients, respectively. Median overall survival (OS) was 15 months (range 2-24 months) from GBM diagnosis. This study expands the clinical and pathologic spectrum of pineal region GBM, and provides the first report of the genetic landscape of these tumors.
引用
收藏
页码:63 / 73
页数:11
相关论文
共 50 条
  • [41] Genetic alteration analysis of non-pediatric diffuse midline glioma, H3 K27-altered
    Jang, Hanbin
    Moon, Seyoung
    Kwon, Hyun Jung
    Lee, Sejoon
    Choe, Gheeyoung
    Lee, Kyu Sang
    HUMAN PATHOLOGY, 2024, 154
  • [42] Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas
    Tanrikulu, Bahattin
    Yasar, Ahmet Harun
    Canpolat, Cengiz
    corapcioglu, Funda
    Tezcanli, Evrim
    Abacioglu, Ufuk
    Danyeli, Ayca Ersen
    Ozek, M. Memet
    JOURNAL OF NEURO-ONCOLOGY, 2023, 163 (03) : 565 - 575
  • [43] Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis
    Aboian, M. S.
    Tong, E.
    Solomon, D. A.
    Kline, C.
    Gautam, A.
    Vardapetyan, A.
    Tamrazi, B.
    Li, Y.
    Jordan, C. D.
    Felton, E.
    Weinberg, B.
    Braunstein, S.
    Mueller, S.
    Cha, S.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2019, 40 (11) : 1804 - 1810
  • [44] Diffuse midline gliomas with histone H3-K27M mutation: A rare case with PNET-like appearance and neuropil-like islands
    Gao, Yue
    Feng, Yang-Yang
    Yu, Juan-Han
    Li, Qing-Chang
    Qiu, Xue-Shan
    Wang, En-Hua
    NEUROPATHOLOGY, 2018, 38 (02) : 165 - 170
  • [45] Identification of prognostic imaging biomarkers in H3 K27-altered diffuse midline gliomas in adults: impact of tumor oxygenation imaging biomarkers on survival
    Sim, Yongsik
    Choi, Kaeum
    Han, Kyunghwa
    Choi, Seo Hee
    Lee, Narae
    Park, Yae Won
    Shin, Na-Young
    Ahn, Sung Soo
    Chang, Jong Hee
    Kim, Se Hoon
    Lee, Seung-Koo
    NEURORADIOLOGY, 2024, 66 (09) : 1581 - 1591
  • [46] Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations
    Solomon, David A.
    Wood, Matthew D.
    Tihan, Tarik
    Bollen, Andrew W.
    Gupta, Nalin
    Phillips, Joanna J. J.
    Perry, Arie
    BRAIN PATHOLOGY, 2016, 26 (05) : 569 - 580
  • [47] Non-Invasive Prediction of Survival Time of Midline Glioma Patients Using Machine Learning on Multiparametric MRI Radiomics Features
    Deng, Da-Biao
    Liao, Yu-Ting
    Zhou, Jiang-Fen
    Cheng, Li-Na
    He, Peng
    Wu, Sheng-Nan
    Wang, Wen-Sheng
    Zhou, Quan
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [48] Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas by Detection of H3F3A K27M Mutation in Circulating Tumor DNA of Cerebrospinal Fluid
    Shibuma, Satoshi
    On, Jotaro
    Natsumeda, Manabu
    Koyama, Akihide
    Takahashi, Haruhiko
    Watanabe, Jun
    Mitobe, Masaki
    Nakata, Satoshi
    Tanaka, Yuki
    Tsukamoto, Yoshihiro
    Okada, Masayasu
    Yoshimura, Junichi
    Tada, Mari
    Shimizu, Hiroshi
    Oya, Soichi
    Murai, Junko
    Okamoto, Kouichirou
    Kawashima, Hiroyuki
    Kakita, Akiyoshi
    Oishi, Makoto
    PEDIATRIC BLOOD & CANCER, 2025, 72 (04)
  • [49] The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age
    Vuong, Huy Gia
    Tam N M Ngo
    Hieu Trong Le
    Dunn, Ian F.
    JOURNAL OF NEURO-ONCOLOGY, 2022, 158 (03) : 405 - 412
  • [50] Clinico-Pathological Features of Diffuse Midline Glioma, H3 K27-Altered in Adults: A Comprehensive Review of the Literature with an Additional Single-Institution Case Series
    Broggi, Giuseppe
    Salzano, Serena
    Failla, Maria
    Barbagallo, Giuseppe Maria Vincenzo
    Certo, Francesco
    Zanelli, Magda
    Palicelli, Andrea
    Zizzo, Maurizio
    Koufopoulos, Nektarios
    Magro, Gaetano
    Caltabiano, Rosario
    DIAGNOSTICS, 2024, 14 (23)